Coherus Biosciences Inc (NASDAQ:CHRS)

28.41
Delayed Data
As of Mar 27
 +1.44 / +5.34%
Today’s Change
12.27
Today|||52-Week Range
33.30
+74.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$946.7M

Company Description

Coherus BioSciences, Inc. is a biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize biosimilar therapeutics worldwide. Its clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor, a substance in the body that is involved in the inflammatory response; and a long-acting form of granulocyte colony-stimulating factor, a beneficial substance in the body that stimulates production of granulocytes (a type of white blood cell) in order to promote the body's ability to fight infections. Coherus BioSciences was founded by Dennis M. Lanfear and Stuart E. Builder in September 2010 and is headquartered in Redwood City, CA.

Contact Information

Coherus BioSciences, Inc.
201 Redwood Shores Parkway
Redwood City California 94065
P:(650) 649-3530
Investor Relations:
(650) 649-3526

Employees

Shareholders

Mutual fund holders6.08%
Individual stakeholders46.82%
Other institutional14.64%

Top Executives

Denny M. LanfearChairman, President & Chief Executive Officer
Jean-Frédéric ViretChief Financial Officer
Alan C. HermanChief Scientific Officer
Peter K. WatlerChief Technical Officer
Barbara K. FinckChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account